EE337 Cost-Effectiveness of Nirmatrelvir/Ritonavir in High-Risk Swedish Adults Including Post-Acute COVID Syndrome (PACS) From a Societal Perspective
Dec 1, 2023, 00:00
10.1016/j.jval.2023.09.603
https://www.valueinhealthjournal.com/article/S1098-3015(23)03733-6/fulltext
Title :
EE337 Cost-Effectiveness of Nirmatrelvir/Ritonavir in High-Risk Swedish Adults Including Post-Acute COVID Syndrome (PACS) From a Societal Perspective
Citation :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(23)03733-6&doi=10.1016/j.jval.2023.09.603
First page :
Section Title :
Open access? :
No
Section Order :
10092